Navid Masoumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Navid Masoumi has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Amir Alinejad Khorram
Urology Department, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publications - Atoosa Gharib
Department of Pathology, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 shared publications Mohammad Soleimani
Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications- Mohammad Soleimani
Men's health and reproductive health research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Farzad Allameh
Men’s Health & Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Milad Fooladgar
Clinical Research Development Center, Shahid Modarres Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Vol. 50 (8) , 530-538
Clinical Predictive Factors for Reproductive Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Radical Cystectomy Cases from Two Tertiary Centers
The preservation of reproductive organs in females with muscle-invasive bladder cancer (MIBC) might improve reproductive and sexual function. This study aimed to identify potential clinical risk factors for reproductive organ involvement (ROI) using preoperative data from transurethral resection of tumor (TURT) reports and imaging findings. This retrospective analysis was conducted on 143 women with bladder cancer who underwent radical cystectomy (RC) at Modarres and Labafinejad Medical Centers in Tehran, Iran, between 2010 and 2019. Demographic, clinical, and pathological data, along with follow-up reports, were collected from medical records and analyzed. The mean age of the participants was 69.17±10.62 years, with an ROI rate of 16.8%. The vagina was the predominantly involved organ. Significant independent risk factors for ROI included clinical T stage (P=0.042), bladder neck or trigonal location of the tumor (P 5 cm (P=0.002), presence of carcinoma in situ (CIS) (P=0.014), lymphovascular invasion in TURT reports (P=0.002), and preoperative hydronephrosis in imaging (P<0.001). Patients with ROI demonstrated significantly lower 5-year survival rates than those without ROI, with overall survival rate of 20.8% versus 63.9% and cancer-specific survival rate of 19% versus 64.8%, respectively. This study represented a comprehensive analysis of preoperative TURT and imaging predictors of ROI. Clinical T stage, tumor location, maximum tumor size, concomitant CIS, presence of lymphovascular invasion, and hydronephrosis were identified as significant preoperative clinical factors associated with ROI. These findings might help guide surgical planning for organ preservation in female MIBC patients.
- 1 August 2025
- Vol. 50 (8) , 530-538
Open AccessClinical Predictive Factors for Reproductive Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Radical Cystectomy Cases from Two Tertiary Centers
The preservation of reproductive organs in females with muscle-invasive bladder cancer (MIBC) might improve reproductive and sexual function. This study aimed to identify potential clinical risk factors for reproductive organ involvement (ROI) using preoperative data from transurethral resection of tumor (TURT) reports and imaging findings. This retrospective analysis was conducted on 143 women with bladder cancer who underwent radical cystectomy (RC) at Modarres and Labafinejad Medical Centers in Tehran, Iran, between 2010 and 2019. Demographic, clinical, and pathological data, along with follow-up reports, were collected from medical records and analyzed. The mean age of the participants was 69.17±10.62 years, with an ROI rate of 16.8%. The vagina was the predominantly involved organ. Significant independent risk factors for ROI included clinical T stage (P=0.042), bladder neck or trigonal location of the tumor (P 5 cm (P=0.002), presence of carcinoma in situ (CIS) (P=0.014), lymphovascular invasion in TURT reports (P=0.002), and preoperative hydronephrosis in imaging (P<0.001). Patients with ROI demonstrated significantly lower 5-year survival rates than those without ROI, with overall survival rate of 20.8% versus 63.9% and cancer-specific survival rate of 19% versus 64.8%, respectively. This study represented a comprehensive analysis of preoperative TURT and imaging predictors of ROI. Clinical T stage, tumor location, maximum tumor size, concomitant CIS, presence of lymphovascular invasion, and hydronephrosis were identified as significant preoperative clinical factors associated with ROI. These findings might help guide surgical planning for organ preservation in female MIBC patients.
- Open Access
- 1 July 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
Investigating the Incidence of Contralateral Metachronous Testicular Cancer Following Radical Orchidectomy
Background: Testicular cancer is the most common malignancy in males aged 15 - 40 years. Although germ cell tumors (GCTs) account for the majority of cases, metachronous contralateral testicular cancer is rare. Objectives: This study aimed to evaluate the incidence of metachronous contralateral testicular cancer in patients without known risk factors, to assess the necessity of routine contralateral testicular biopsy. Methods: This historical cohort study included 220 patients under 40 years old with unilateral testicular GCT diagnosed before March 2019 at Shahid Modares Hospital, Tehran, Iran. Patients with cryptorchidism, family history of testicular cancer, testicular atrophy, or immunodeficiency were excluded. Finally, 95 patients completed at least a 5-year follow-up. Data were collected from medical records and patient interviews. Results: The mean age at diagnosis was 30.5 years. Seminoma was the most common pathology (50.5%). Right-sided tumors were more frequent (56.8%). After a minimum follow-up of 5 years, only one (1.05%) patient developed metachronous contralateral testicular cancer, occurring 5.5 years after the initial diagnosis. Conclusions: The incidence of metachronous contralateral testicular cancer in patients without risk factors was low (1.05%). Therefore, in strictly low-risk patients (no cryptorchidism, family history, or atrophy), routine contralateral testicular biopsy may not be necessary given the low incidence. Further studies with larger sample sizes are recommended to establish definitive guidelines.
- 1 July 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
Open AccessInvestigating the Incidence of Contralateral Metachronous Testicular Cancer Following Radical Orchidectomy
Background: Testicular cancer is the most common malignancy in males aged 15 - 40 years. Although germ cell tumors (GCTs) account for the majority of cases, metachronous contralateral testicular cancer is rare. Objectives: This study aimed to evaluate the incidence of metachronous contralateral testicular cancer in patients without known risk factors, to assess the necessity of routine contralateral testicular biopsy. Methods: This historical cohort study included 220 patients under 40 years old with unilateral testicular GCT diagnosed before March 2019 at Shahid Modares Hospital, Tehran, Iran. Patients with cryptorchidism, family history of testicular cancer, testicular atrophy, or immunodeficiency were excluded. Finally, 95 patients completed at least a 5-year follow-up. Data were collected from medical records and patient interviews. Results: The mean age at diagnosis was 30.5 years. Seminoma was the most common pathology (50.5%). Right-sided tumors were more frequent (56.8%). After a minimum follow-up of 5 years, only one (1.05%) patient developed metachronous contralateral testicular cancer, occurring 5.5 years after the initial diagnosis. Conclusions: The incidence of metachronous contralateral testicular cancer in patients without risk factors was low (1.05%). Therefore, in strictly low-risk patients (no cryptorchidism, family history, or atrophy), routine contralateral testicular biopsy may not be necessary given the low incidence. Further studies with larger sample sizes are recommended to establish definitive guidelines.
- Open Access
- 3 April 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
Prophylactic Neostigmine Infusion After Radical Cystectomy; Phase I Clinical Trial
Background: Postoperative ileus (POI) occurs in 10% to 30% of patients following abdominal surgeries, leading to prolonged hospitalization, increased complications, and elevated treatment costs. Various strategies have been proposed to prevent POI and its associated complications. Neostigmine, an acetylcholinesterase inhibitor, has demonstrated effectiveness in treating acute colonic pseudo-obstruction (Ogilvie's syndrome). However, concerns exist regarding its use following surgeries that involve intestinal manipulation, and its impact on reducing the incidence of POI after radical cystectomy and urinary diversion has not been adequately investigated. Objectives: This study aims at assessing the safety of neostigmine administration after radical cystectomy and urinary diversion, marking the first phase of a clinical trial. Methods: Twenty-four hours after radical cystectomy, 1 mg of neostigmine was administered intravenously to the selected group of patients. Drug-related complications were carefully monitored. Results: A total of 25 patients, with an average age of 63.20 ± 8.85 years, were included in the study. One patient expired 5 days post-surgery due to sepsis related to intra-abdominal abscess formation without intestinal leakage. In the remaining patients, drug-related complications were mild and self-limited. Conclusions: This study indicates that intravenous administration of 1 mg of neostigmine is relatively safe for patients undergoing radical cystectomy. Future phases of the clinical trial should focus on evaluating the efficacy of neostigmine in preventing POI following radical cystectomy.
- 3 April 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
Open AccessProphylactic Neostigmine Infusion After Radical Cystectomy; Phase I Clinical Trial
Background: Postoperative ileus (POI) occurs in 10% to 30% of patients following abdominal surgeries, leading to prolonged hospitalization, increased complications, and elevated treatment costs. Various strategies have been proposed to prevent POI and its associated complications. Neostigmine, an acetylcholinesterase inhibitor, has demonstrated effectiveness in treating acute colonic pseudo-obstruction (Ogilvie's syndrome). However, concerns exist regarding its use following surgeries that involve intestinal manipulation, and its impact on reducing the incidence of POI after radical cystectomy and urinary diversion has not been adequately investigated. Objectives: This study aims at assessing the safety of neostigmine administration after radical cystectomy and urinary diversion, marking the first phase of a clinical trial. Methods: Twenty-four hours after radical cystectomy, 1 mg of neostigmine was administered intravenously to the selected group of patients. Drug-related complications were carefully monitored. Results: A total of 25 patients, with an average age of 63.20 ± 8.85 years, were included in the study. One patient expired 5 days post-surgery due to sepsis related to intra-abdominal abscess formation without intestinal leakage. In the remaining patients, drug-related complications were mild and self-limited. Conclusions: This study indicates that intravenous administration of 1 mg of neostigmine is relatively safe for patients undergoing radical cystectomy. Future phases of the clinical trial should focus on evaluating the efficacy of neostigmine in preventing POI following radical cystectomy.
- 21 January 2025
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (6) , 395.e1-395.e6
Concordance between intraoperative macroscopic evaluation and permanent section analysis of tumor bed margin in partial nephrectomy: A prospective study
- 21 January 2025
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (6) , 395.e1-395.e6
Concordance between intraoperative macroscopic evaluation and permanent section analysis of tumor bed margin in partial nephrectomy: A prospective study
- 12 December 2024
- Published by SAGE Publications in Urologia Journal
- Vol. 92 (2) , 259-266
Potential value of Prostate Cancer Antigen 3 score in prediction of final cancer pathology parameters in radical prostatectomy patients
Background: To evaluate the potential capability of preoperative urinary Prostate Cancer Antigen 3 (PCA3) in predicting adverse pathologic features in patients with any- risk prostate cancer undergoing open retro-pubic radical prostatectomy. Methods: Sixty-one biopsy-proven, clinically localized prostate cancer patients who underwent open radical prostatectomy were included in a prospectively designed cohort to evaluate the association of PCA3 score with various Adverse Pathologic Features (APF). The Area Under the Curve (AUC) of the Receiver Operating Characteristics (ROC) curve was used to quantify the predictive accuracy of PCA3 and a cut-off point was calculated to determine the predictability potential of PCA3 in foretelling the study parameters. Results: Patients with APFs (e.g. extra-capsular extension, higher tumor volume, etc.) had a higher mean level of PCA3 compared to patients without these features, with statistically significant differences. PCA3 was a significant predictor of any APFs except perineural invasion in our study cohort. Conclusion: Increasing PCA3 level was associated with any APFs except perineural invasion in our study, which comprised mostly of intermediate and high-risk prostate cancer patients. Therefore, PCA3 could be used as an adjunctive measure in selecting patients for definitive treatments.
- 12 December 2024
- Published by SAGE Publications in Urologia Journal
- Vol. 92 (2) , 259-266
Potential value of Prostate Cancer Antigen 3 score in prediction of final cancer pathology parameters in radical prostatectomy patients
Background: To evaluate the potential capability of preoperative urinary Prostate Cancer Antigen 3 (PCA3) in predicting adverse pathologic features in patients with any- risk prostate cancer undergoing open retro-pubic radical prostatectomy. Methods: Sixty-one biopsy-proven, clinically localized prostate cancer patients who underwent open radical prostatectomy were included in a prospectively designed cohort to evaluate the association of PCA3 score with various Adverse Pathologic Features (APF). The Area Under the Curve (AUC) of the Receiver Operating Characteristics (ROC) curve was used to quantify the predictive accuracy of PCA3 and a cut-off point was calculated to determine the predictability potential of PCA3 in foretelling the study parameters. Results: Patients with APFs (e.g. extra-capsular extension, higher tumor volume, etc.) had a higher mean level of PCA3 compared to patients without these features, with statistically significant differences. PCA3 was a significant predictor of any APFs except perineural invasion in our study cohort. Conclusion: Increasing PCA3 level was associated with any APFs except perineural invasion in our study, which comprised mostly of intermediate and high-risk prostate cancer patients. Therefore, PCA3 could be used as an adjunctive measure in selecting patients for definitive treatments.
- Open Access
- 23 August 2024
- Published by Elsevier in Urology Case Reports
- Vol. 56, 102830
From pure testicular Teratoma to primitive neuroectodermal tumor: Successful management of Teratoma malignant transformation with widespread metastases in a young adult
- 23 August 2024
- Published by Elsevier in Urology Case Reports
- Vol. 56, 102830
Open AccessFrom pure testicular Teratoma to primitive neuroectodermal tumor: Successful management of Teratoma malignant transformation with widespread metastases in a young adult
- Open Access
- 7 July 2024
- Published by Brieflands in International Journal of Cancer Management
- Vol. 17 (1)
Two-Stage Radical Cystoprostatectomy in a Complicated Patient: A Case Report
Introduction: Radical cystectomy plays the main role in the treatment of muscle-invasive and high-grade bladder cancers; however, it still has significant rates of perioperative complications and mortality. The risk of complications is higher in elderly patients with multiple comorbidities. In certain patients, due to simultaneous comorbidities, it becomes challenging to perform long-term orthotopic radical cystectomy surgery. Case Presentation: In this article, we analyzed a 61-year-old man who was a candidate for radical cystectomy surgery due to muscle-invasive bladder cancer. However, due to simultaneous comorbidities and the lengthy surgery time, it was not feasible to perform orthotopic surgery in a single stage. Consequently, the patient's surgery was carried out in two separate stages. Conclusions: Conducting a radical cystectomy in two stages may aid in minimizing surgical complications, thus enabling patients to benefit from the advantages of urinary diversion through an orthotopic neobladder.
- 7 July 2024
- Published by Brieflands in International Journal of Cancer Management
- Vol. 17 (1)
Open AccessTwo-Stage Radical Cystoprostatectomy in a Complicated Patient: A Case Report
Introduction: Radical cystectomy plays the main role in the treatment of muscle-invasive and high-grade bladder cancers; however, it still has significant rates of perioperative complications and mortality. The risk of complications is higher in elderly patients with multiple comorbidities. In certain patients, due to simultaneous comorbidities, it becomes challenging to perform long-term orthotopic radical cystectomy surgery. Case Presentation: In this article, we analyzed a 61-year-old man who was a candidate for radical cystectomy surgery due to muscle-invasive bladder cancer. However, due to simultaneous comorbidities and the lengthy surgery time, it was not feasible to perform orthotopic surgery in a single stage. Consequently, the patient's surgery was carried out in two separate stages. Conclusions: Conducting a radical cystectomy in two stages may aid in minimizing surgical complications, thus enabling patients to benefit from the advantages of urinary diversion through an orthotopic neobladder.
- Open Access
- 14 March 2024
- Published by Brieflands in International Journal of Cancer Management
- Vol. 17 (1)
Tactile Ligation Technique for Renal Vascular Control During Open Radical Nephrectomy
- 14 March 2024
- Published by Brieflands in International Journal of Cancer Management
- Vol. 17 (1)
Open AccessTactile Ligation Technique for Renal Vascular Control During Open Radical Nephrectomy